Vericel Corporation (NASDAQ:VCEL) rose 6.6% on Monday . The company traded as high as $4.95 and last traded at $4.85. Approximately 1,099,970 shares changed hands during trading, an increase of 124% from the average daily volume of 491,428 shares. The stock had previously closed at $4.55.
VCEL has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of Vericel Corporation in a research report on Tuesday, June 20th. They set a “buy” rating and a $6.00 price objective for the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 price objective on shares of Vericel Corporation in a research report on Thursday, August 10th.
The firm’s 50 day moving average price is $3.81 and its 200 day moving average price is $3.11. The firm’s market capitalization is $159.20 million.
Vericel Corporation (NASDAQ:VCEL) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.16. The business had revenue of $16.95 million for the quarter. On average, analysts expect that Vericel Corporation will post ($0.63) earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. First Washington CORP bought a new position in shares of Vericel Corporation during the 2nd quarter worth about $2,230,000. Perkins Capital Management Inc. increased its position in shares of Vericel Corporation by 12.6% during the 2nd quarter. Perkins Capital Management Inc. now owns 257,600 shares of the biotechnology company’s stock worth $850,000 after purchasing an additional 28,850 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of Vericel Corporation by 73.3% during the 1st quarter. Stonepine Capital Management LLC now owns 3,265,323 shares of the biotechnology company’s stock worth $9,143,000 after purchasing an additional 1,381,523 shares in the last quarter. Archon Capital Management LLC acquired a new stake in shares of Vericel Corporation during the 2nd quarter worth about $4,412,000. Finally, Vanguard Group Inc. increased its position in shares of Vericel Corporation by 7.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after purchasing an additional 88,645 shares in the last quarter. 33.84% of the stock is owned by institutional investors.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.